Literature DB >> 29534587

An extensive study of the mechanism of prostate cancer metastasis.

Y Wang, W Guo, H Xu, X Zhu, T Yu, Z Jiang, Q Jiang, X Gang.   

Abstract

The study aimed to identify the pivotal genes and pathways involved in prostate cancer metastasis. Using the expression profile dataset GSE7930, downloaded from the Gene Expression Omnibus (GEO) database, differentially expressed genes (DEGs) between primary and highly metastatic prostate cell samples were screened, followed by functional analysis and tumor associated genes (TAG) screening. Protein-protein interaction (PPI) network of DEGs was constructed and module analysis was performed. The expression of DEGs and pathway related genes were evaluated by PCR analysis and the migra- tion ability of prostate tumor cells was observed after FABP4-siRNA blocking. Upregulated FABP4 and GK were signifi- cantly enriched in the PPAR signaling pathway, whereas downregulated IGFBP3 and THBS1 were involved in p53 signaling pathway. Among the identified DEGs, 4 downregulated genes (IGFBP3, NPP4B, THBS1, and PCDH1) and 2 upregulated genes (GJA1 and TUSC3) were TAGs. The module was associated with focal adhesion, ECM-receptor interaction, p53 signaling, and gap junction pathways with the hub node GJA1. After FABP4 silencing by siRNAs in LNcap and metastatic DU-145 cells, the numbers of migrated cells were all significantly declined. The expressions of IGFBP3, TP53 and PPAR were significantly lower in DU-145 cells than in LNcap cells. In conclusion, FABP4, IGFBP3, THBS1, and GJA1 were determined to be potential markers of prostate cancer cell metastasis, and P53, PPAR and gap junction pathways were found to play important roles in prostate cancer cell metastasis. This study may provide helpful guidelines for clinical management.

Entities:  

Keywords:  differentially expressed genes tumor associated genes.; metastasis; microarray profile; prostate cancer

Mesh:

Substances:

Year:  2018        PMID: 29534587     DOI: 10.4149/neo_2018_161217N648

Source DB:  PubMed          Journal:  Neoplasma        ISSN: 0028-2685            Impact factor:   2.575


  7 in total

1.  Comprehensive analysis and identification of key genes and signaling pathways in the occurrence and metastasis of cutaneous melanoma.

Authors:  Hanying Dai; Lihuang Guo; Mingyue Lin; Zhenbo Cheng; Jiancheng Li; Jinxia Tang; Xisha Huan; Yue Huang; Keqian Xu
Journal:  PeerJ       Date:  2020-11-19       Impact factor: 2.984

2.  Identification of critically carcinogenesis-related genes in basal cell carcinoma.

Authors:  Jie Dai; Kang Lin; Yan Huang; Yan Lu; Wen-Qi Chen; Xiao-Rong Zhang; Bang-Shun He; Yu-Qin Pan; Shu-Kui Wang; Wei-Xin Fan
Journal:  Onco Targets Ther       Date:  2018-10-15       Impact factor: 4.147

3.  GJA1 Expression and Its Prognostic Value in Cervical Cancer.

Authors:  Silu Meng; Xinran Fan; Jianwei Zhang; Ran An; Shuang Li
Journal:  Biomed Res Int       Date:  2020-11-24       Impact factor: 3.411

4.  FABP4 deactivates NF-κB-IL1α pathway by ubiquitinating ATPB in tumor-associated macrophages and promotes neuroblastoma progression.

Authors:  Lei Miao; Zhenjian Zhuo; Jue Tang; Xiaomei Huang; Jiabin Liu; Hai-Yun Wang; Huimin Xia; Jing He
Journal:  Clin Transl Med       Date:  2021-04

5.  High expression of ladinin-1 (LAD1) predicts adverse outcomes: a new candidate docetaxel resistance gene for prostatic cancer (PCa).

Authors:  Jianping Li; Ziming Wang; Chong Tie
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

6.  Boosting curcumin activity against human prostatic cancer PC3 cells by utilizing scorpion venom conjugated phytosomes as promising functionalized nanovesicles.

Authors:  Mohammed W Al-Rabia; Nabil A Alhakamy; Waleed Y Rizg; Adel F Alghaith; Osama A A Ahmed; Usama A Fahmy
Journal:  Drug Deliv       Date:  2022-12       Impact factor: 6.419

7.  MiR-206 improves intervertebral disk degeneration by targeting GJA1.

Authors:  Peng Zhou; Peng Xu; Wantao Yu; Huan Li
Journal:  J Orthop Surg Res       Date:  2022-03-12       Impact factor: 2.359

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.